Serbian scientists experiment with mealworms to degrade polystyrene
BELGRADE (Reuters) -Serbian scientists have been experimenting with mealworms as a way to break down polystyrene.
Larisa Ilijin, a principal research fellow at Belgrade's Institute for Biology, said the scientists had discovered that mealworms can digest various plastics, including polystyrene, which is used in packaging, insulation and food containers.
In the project endorsed by the government and the United Nations' agency for international development, UNDP, and other international donors, they have been including the polystyrene in the regular food of the larval form of the yellow mealworm beetle, or Tenebrio molitor.
They habitually eat more or less anything, but need the training to eat the plastic products.
"We have larvae that have been adapted over a long time to biodegrade plastic, to be as efficient as possible in the process," Ilijin told Reuters.
She said the bacteria living in their guts break down the plastic into carbon dioxide and water, and showed no evidence of leaving microplastic residue in their innards or faeces.
The work builds on similar research projects in the U.S. and Africa.
Serbia, which hopes to join the EU, recycles only 15% of municipal waste, far below the EU's 55% target and less than 2% of household waste.
Over 84% of waste ends up in about 3,000 landfill sites, often unregulated and filled with plastic, cardboard, paper and organic waste. It is looking for ways to meet EU waste treatment standards.
"Styrofoam takes over 500 years to decompose in nature ... this would be one of the good ways for solving the problem of plastic waste in nature," Ilijin said.
The institute has given Belgrade-based Belinda Animals several containers of the mealworms. It is now breeding them and hoping to attract a network of similar farms.
'When breaking down 1 kg of Styrofoam, larvae emit one to two grams of carbon dioxide ... If we incinerate it ... (Styrofoam) emits over 4,000 times more,' owner Boris Vasiljev said.
He also envisages the larvae being used as animal feed, should it reach a large commercial scale.
The use of mealworms is still in its infancy, Ilijin said, as Serbia still needs to adopt regulations that would allow the use and sale of insect products for animal fodder.
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
an hour ago
- Associated Press
Dr. Nikola Cihoric Redefines Clinical Research Through Innovation, Technology, and Data
ZURICH, SWITZERLAND, August 21, 2025 / / -- Bridging Medicine, Research, and Technology for Patient-Centric Solutions Dr. Nikola Cihoric, founder and visionary behind Wemedoo AG, is redefining clinical research by merging technology, innovation, medicine, and data into a seamless ecosystem that empowers healthcare professionals and researchers alike. With over 15 years of experience in radiation oncology and a deep commitment to clinical data standardization, Dr. Cihoric is setting a new standard in the way clinical trials are conducted worldwide. A Vision Born from Real Clinical Challenges Wemedoo was born from Dr. Cihoric's firsthand frustration with fragmented healthcare systems and inefficient clinical workflows. 'I observed the paper world and sloppy digitalization that slowed treatment delivery and overburdened medical staff,' he explains. His focus on data standardization and cross-sector collaboration led to the development of an early prototype, oopus (initially SmartOncology), which received support from the Swiss Cancer Foundation. Building on this experience, Wemedoo developed its unique approach, which eliminates silos, enhances transparency, and gives researchers full control across the clinical data lifecycle. Learn more about Dr. Cihoric's vision in the Xraised interview. Transforming Clinical Trials Through Technology Unlike traditional clinical trial solutions that rely on multiple disconnected systems, Wemedoo's oomnia system integrates EDC, CTMS, eTMF, eConsent, RTSM, and advanced reporting in a single, unified, and interoperable environment. This approach eliminates costly integrations, reduces errors, and ensures data consistency across every stage of a trial. 'By using technology to unify processes, we save time, reduce errors, and provide real-time insights for clinicians and researchers,' Dr. Cihoric notes. 'Our no-code configuration also allows rapid adaptation to evolving trial requirements, ensuring flexibility without compromising quality.' Ethical AI and Data-Driven Innovation Wemedoo integrates AI into oomnia practically and responsibly, focusing on automating processes where it delivers immediate value without unnecessary risks, essential in a highly regulated industry. Their work is guided by explainability and transparency, from AI-driven risk assessment tools for protocol design to semantic mapping engines that cut data processing timelines from months to days. Wemedoo is also exploring agentic AI to support operational decision-making, always with a 'man-in-control' philosophy to ensure accountability. What makes this possible is oomnia's semantic foundation, structured data, common data elements, and standard vocabularies, which keep outcomes reproducible, interpretable, and aligned with regulatory frameworks. Beyond technology, Wemedoo collaborates with public institutions and publish in peer-reviewed journals, reinforcing their belief that AI is only meaningful if it strengthens trust, transparency, and data integrity. Balancing Clinical Practice and Product Development Despite his active role at Wemedoo, Dr. Cihoric continues to work in a leading academic hospital. This dual role allows him to translate real-world clinical challenges into actionable system improvements. 'Being close to patients and clinical teams keeps me grounded in reality, ensuring that our technology delivers tangible benefits,' he says. Long-Term Vision for Clinical Research Looking ahead, Dr. Cihoric aims to remove barriers between clinical practice and research, investing in education, resources, and stakeholder alignment to ultimately improve patient outcomes. 'The goal is to create a future where innovation, technology, and real-world data converge seamlessly to benefit patients worldwide,' he asserts. About Dr. Nikola Cihoric Dr. Nikola Cihoric is a radiation oncologist, researcher, and founder of Wemedoo AG, with expertise in clinical data standardization, AI integration, and oncology innovation. He has published over 35 scientific papers and actively contributed to international standards groups such as mCODE, CodeX, HL7/FHIR, and CDISC. For more information on Dr. Nikola Cihoric and Wemedoo's groundbreaking work, visit Wemedoo and explore insights from Xraised ( ). Media and Business Inquiries General contact: [email protected] Business development: [email protected] Website: LinkedIn: Wemedoo AG. Gianmarco Giordaniello Xraised email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
2 hours ago
- Associated Press
AMD Dublin Hosts Irish Technovation Finals
In Dublin, Ireland, AMD hosted a day of fun, learning and inspiration for young women students from all over Ireland interested in STEM in 2024. The annual event showcases the projects of women students who participate in the Technovation Challenge, a global program that empowers girls to solve real-world problems using technology. Students work in teams to develop mobile apps that address issues like health, education, environment and social volunteers welcomed more than 100 students from ten counties across Ireland, along with their mentors, teachers and parents. Students demoed their apps, received feedback from AMD judges, networked with other participants and enjoyed a bean bag zone, robotics room, table tennis, karaoke and Xbox games. The day wrapped up with an award ceremony, announcing winners in the junior and senior the event, AMD in Dublin collaborated with Teen-Turn, a volunteer organization that helps girls interested in STEM, especially those from disadvantaged areas or backgrounds.'Our team cannot emphasize this enough: AMD is a true partner in change making,' said Dr. Joanne Dolan, Teen-Turn end of 2024, the AMD Foundation awarded a $100,000 grant to Technovation to support young women across eight countries in developing skills in AI and entrepreneurship. Originally published in AMD 2024-25 Corporate Responsibility Report. Visit 3BL Media to see more multimedia and stories from AMD
Medscape
3 hours ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.
